Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2009 4
2010 8
2011 5
2012 6
2013 9
2014 14
2015 6
2016 12
2017 16
2018 32
2019 34
2020 33
2021 32
2022 33
2023 21
2024 26
2025 31
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Results by year

Filters applied: . Clear all
Page 1
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the ca …
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about …
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase …
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with …
Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis.
Guan X, Zhang S, Liu J, Wu F, Zhou L, Liu Y, Su N. Guan X, et al. Front Pharmacol. 2022 Sep 30;13:998441. doi: 10.3389/fphar.2022.998441. eCollection 2022. Front Pharmacol. 2022. PMID: 36249825 Free PMC article.
However, the cardiovascular safety of febuxostat and allopurinol is still controversial. The purpose of our study is to evaluate the cardiovascular safety of the two drugs in patients with gout using one-stage and two-stage meta-analysis. ...Randomized …
However, the cardiovascular safety of febuxostat and allopurinol is still controversial. The purpose of our study is to evalua …
Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.
Ghossan R, Aitisha Tabesh O, Fayad F, Richette P, Bardin T. Ghossan R, et al. J Clin Rheumatol. 2024 Mar 1;30(2):e46-e53. doi: 10.1097/RHU.0000000000002045. Epub 2023 Dec 20. J Clin Rheumatol. 2024. PMID: 38115182
We aimed to compare the cardiovascular outcomes in the most pertinent trials of febuxostat compared with controls. ...Cardiovascular outcomes in the majority of White males with gout treated with febuxostat were reassuring when compared with all …
We aimed to compare the cardiovascular outcomes in the most pertinent trials of febuxostat compared with controls. ...Cardi …
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L, Wang B, Pan Y, Lu Y, Cheng R. Gao L, et al. Clin Cardiol. 2021 Jul;44(7):907-916. doi: 10.1002/clc.23643. Epub 2021 May 20. Clin Cardiol. 2021. PMID: 34013998 Free PMC article.
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...We did a systematic review and meta-analysis of included clinical trials to evaluate the cardiovascular safety of febuxostat compared …
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...We did …
Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis.
Zhang S, Xu T, Shi Q, Li S, Wang L, An Z, Su N. Zhang S, et al. Front Med (Lausanne). 2021 Jun 15;8:698437. doi: 10.3389/fmed.2021.698437. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34211992 Free PMC article.
Background: Hyperuricemia is a common metabolic disease and has become a public health problem because of its increasing prevalence and association with comorbidities. Allopurinol and febuxostat are recommended as the first-line treatments for hyperuricemia and gout …
Background: Hyperuricemia is a common metabolic disease and has become a public health problem because of its increasing prevalence and asso …
Gout: Rapid Evidence Review.
Clebak KT, Morrison A, Croad JR. Clebak KT, et al. Am Fam Physician. 2020 Nov 1;102(9):533-538. Am Fam Physician. 2020. PMID: 33118789 Free article. Review.
Gout is characterized by swelling, pain, or tenderness in a peripheral joint or bursa, including the development of a tophus. ...Allopurinol and febuxostat are used to prevent flare-ups, although febuxostat is associated with an increase in all-cause and c …
Gout is characterized by swelling, pain, or tenderness in a peripheral joint or bursa, including the development of a tophus. ...Allo …
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Wang M, Zhang Y, Zhang M, Li H, Wen C, Zhao T, Xie Z, Sun J. Wang M, et al. Ann Palliat Med. 2021 Oct;10(10):10327-10337. doi: 10.21037/apm-21-1564. Epub 2021 Sep 6. Ann Palliat Med. 2021. PMID: 34498481 Free article.
BACKGROUND: To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gout or asymptomatic hyperuricemia. ...There was no difference in the incidence of major cardiovascular events between febuxostat …
BACKGROUND: To evaluate the major cardiovascular (CV) events of febuxostat compared to allopurinol for the treatment of gou …
Update on gout management: what is old and what is new.
Afinogenova Y, Danve A, Neogi T. Afinogenova Y, et al. Curr Opin Rheumatol. 2022 Mar 1;34(2):118-124. doi: 10.1097/BOR.0000000000000861. Curr Opin Rheumatol. 2022. PMID: 34907116 Free PMC article. Review.
Trial data have provided new insights regarding cardiovascular risk with febuxostat. Several new drug therapies are being tested for both urate-lowering efficacy and gout flare management. SUMMARY: Although there have been significant advances in understandin …
Trial data have provided new insights regarding cardiovascular risk with febuxostat. Several new drug therapies are being test …
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH, Lai PH, Xie LS, Qiu SS, Qiu DS, Zhang JX. Deng JH, et al. Clin Transl Sci. 2024 Mar;17(3):e13757. doi: 10.1111/cts.13757. Clin Transl Sci. 2024. PMID: 38488426 Free PMC article.
The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients is uncertain. ...In conclusion, the use of febuxostat, compared with allopurinol among Asian patients, was associated with a significa …
The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients i …
295 results